Thursday 16 October, 2025
Objectives: The glucose Disposition Index (DI) was first introduced Bergman et al. [1] with the purpose of assessing the efficiency…
Read morePoster: Applications- Endocrine
Comparison of Different Population Analysis Approaches to the IVGTT Glucose Minimal Model
Thursday 16 October, 2025
Objectives: Assessment of the performance of several different population approaches to the estimation of population parameters of the intravenous glucose…
Read moreSimultaneous fitting of the Minimal Model to IVGTT and Glucose Clamp Data
Thursday 16 October, 2025
PDF of poster The minimal model of glucose kinetics has been extensively used to provide quantitative estimates of insulin sensitivity…
Read moreModelling of insulin secretion: from beta-cell physiology to sulphonylurea-mediated insulin secretion
Thursday 16 October, 2025
One major aspect of the treatment of Non Insulin Dependent Diabetes Mellitus is the enhancement of insulin secretion by sulphonylureas…
Read moreDetermination of the absolute bioavailability of BI 1356, a substance with non-linear pharmacokinetics, using a population pharmacokinetic modelling approach
Thursday 16 October, 2025
Objectives & Background: BI 1356 is a new dipeptidyl-peptidase IV (DPP IV) inhibitor under clinical development for type 2 diabetes…
Read moreTarget mediated drug disposition model for the DPP-4 inhibitor BI1356 (proposed trade name ONDERO): Is the structure identifiable?
Thursday 16 October, 2025
Objectives: BI 1356 is a DPP-4 inhibitor with non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4….
Read moreBI 1356 (proposed trade name ONDERO) pharmacokinetics and DPP-4 inhibition: Development of a target mediated PKPD model in type 2 diabetic patients
Thursday 16 October, 2025
Objectives: BI 1356 is a novel, highly selective and long acting DPP-4 inhibitor under development for type 2 diabetes mellitus…
Read morePre-Clinical PK/PD Modeling for a Dipeptidyl Peptidase-IV Inhibitor
Thursday 16 October, 2025
Background: Inhibition of Dipeptidyl Peptidase-IV (DPP-IV) is a novel strategy to treat type 2 diabetic patients. Compound X is a…
Read moreIdentification of the Mechanism of Action of a Glucokinase Activator from OGTT Data in Type 2 Diabetics Using an Integrated Glucose-Insulin Model
Thursday 16 October, 2025
Objectives: To demonstrate the ability of a previously developed integrated glucose-insulin model to identify the correct dual mechanism of action…
Read moreAn integrated model for glucose-insulin regulation to describe oral glucose tolerance test data in healthy volunteers
Thursday 16 October, 2025
Introduction: Oral glucose tolerance tests (OGTT) are commonly used in drug development. The study design is less invasive than the…
Read more